Concord Biotech Share Price

NSE: CONCORDBIO

₹ 1,248.50

-₹20.00 (-1.58%)

Last updated 24 Jul, 2026, 15:48 IST

Concord Biotech Share Price Today

As of 25 Jul 2026, Concord Biotech share price is ₹1,248.50. The stock opened at ₹1,268.50, compared to its previous close of ₹1,268.50. During today's trading session, Concord Biotech share price moved in the range of ₹1,238.00 to ₹1,272.20, with an average price of ₹1,255.10 for the day. Looking at its last 52-week, the stock has touched a low of ₹987.00 and a high of ₹1,980.00. On the performance front, Concord Biotech share price has increased by 0.05% over the last six months and is down 35.26% on a year-on-year basis.

₹1,238.00

1.58% down today

₹1,272.20

1D LOW

1D HIGH

Latest Earning

Op Profit TrendUp by 32.40% QoQ

Latest Earning

Net Profit TrendUp by 39.02% QoQ

Latest Earning

Revenue TrendUp by 18.66% QoQ

Stock Performance

OutperformingBeat Nifty by 22.95 % in last 3 month

Shareholding Pattern

DIIDII increased stake by 0.95%

Shareholding Pattern

FIIFII decreased stake by 3.48%

Concord Biotech Returns Calculator

If you would've invested

₹

₹1,000₹1Cr

Historical Returns

1 Year

₹3,31,907-₹1,68,093 (-33.62%)

3 Year

₹6,40,947+₹1,40,947 (+28.19%)

5 Year

₹6,40,947+₹1,40,947 (+28.19%)

₹1,008.80₹1,513.20

Circuit Low

Circuit High

₹987.00₹1,980.00

52-Week Low

52-Week High

Circuit

₹1,008.80

₹1,513.20

52-week

₹987.00

₹1,980.00

Mkt Cap Cr

13,268.00

P/E

40.73

P/B

5.27

ROE

13.54%

D/E

0.00

ROCE

17.99%

Div. Yield

0.74%

EPS(TTM)

25.17

Turnover

0.51

EV/EBITDA

25.28

Net Margin

24.95%

Op. Margin

40.43%

ROA

12.91%

Quick Ratio

0.00

Curr. Ratio

3.80

Mkt Cap Cr

13,268.00

P/E

40.73

P/B

5.27

ROE

13.54%

D/E

0.00

ROCE

17.99%

Div. Yield

0.74%

EPS(TTM)

25.17

Turnover

0.51

EV/EBITDA

25.28

Net Margin

24.95%

Op. Margin

40.43%

ROA

12.91%

Quick Ratio

0.00

Curr. Ratio

3.80

Based on fundamentals, this stock's

Performance

Very Poor

Concord Biotech has not beaten FD return of 7%

Valuation

Overvalued

Concord Biotech appears overvalued compared to its peers

Earnings

Neutral

Concord Biotech earnings growth is positive

Peer Comparison

Peer comparison — key ratios
Name	Mkt Cap Cr	P/E	P/B	ROE	D/E	ROCE	Book Value	Div. Yield	Turnover	EPS(TTM)
Sun Pharmaceutical Industries	4,65,711.00	36.73	5.05	14.85%	0.55	18.72%	18.85	0.91%	0.56	10.90
Divis Laboratories	1,93,860.00	61.36	9.40	16.19%	0.00	21.00%	9.43	0.50%	0.58	98.19
Torrent Pharmaceuticals	1,92,687.00	66.03	17.03	26.76%	1.05	18.30%	16.90	0.90%	0.49	64.75
Cipla	1,12,593.00	33.55	3.27	11.27%	0.00	14.95%	423.36	0.93%	0.44	43.52
Zydus Lifesciences	1,11,082.00	17.39	3.23	19.69%	0.35	20.30%	3.70	0.11%	0.39	35.38
Lupin	1,09,553.00	19.83	4.71	27.01%	0.03	27.44%	3.51	0.78%	0.61	129.18
Mankind Pharma	1,05,607.00	1.05	0.12	12.65%	0.42	12.97%	5.05	0.05%	0.54	49.37
Dr. Reddy's Laboratories	97,364.90	30.58	2.56	11.07%	0.18	12.54%	377.96	0.69%	0.41	38.68
Aurobindo Pharma	88,508.40	25.27	2.34	9.25%	0.19	11.76%	391.14	0.26%	0.48	41.58
Laurus Labs	84,727.30	60.26	10.10	18.21%	0.40	16.70%	97.21	0.12%	0.64	13.72

Concord Biotech Financials

Full statement

Income Statement · Consolidated

Income Statement · Consolidated — all values in INR Crore
Particulars	Mar 2026	Mar 2025	Mar 2024	Mar 2023
Revenue	₹1,054.89	₹1,200.09	₹1,016.94	₹853.17
Other Income	₹52.36	₹44.45	₹33.78	₹35.31
Total Revenue	₹1,107.25	₹1,244.53	₹1,050.72	₹888.48
Total Expenses	₹762.23	₹748.66	₹641.53	₹568.42
Profit Before Tax	₹344.65	₹494.55	₹412.57	₹322.01
Tax	₹85.42	₹122.91	₹104.46	₹81.93
Profit After Tax	₹259.23	₹371.64	₹308.10	₹240.09
EPS - Basic	₹24.78	₹35.52	₹29.45	₹22.95
EPS - Diluted	₹24.78	₹35.52	₹29.45	₹22.95

Cash Flow · Consolidated

Cash Flow · Consolidated — all values in INR Crore
Particulars	Mar 2026	Mar 2025	Mar 2024	Mar 2023
Profit before tax	₹344.65	₹494.55	₹412.57	₹322.01
Income before WC changes	₹381.21	₹524.69	₹450.00	₹368.56
Change in Assets	-₹10.48	-₹216.44	-₹73.97	-₹79.46
Change in Liabilities	-₹3.44	₹45.68	-₹7.21	₹27.17
Change in WC	-₹13.92	-₹170.76	-₹81.18	-₹52.29
Cash flow from Operations	₹266.88	₹244.52	₹265.47	₹246.00
Cash flow from Investing	-₹142.72	-₹159.99	-₹154.61	-₹157.95
Cash flow from Financing	-₹112.88	-₹98.77	-₹99.21	-₹85.22
Total Cash Flow	₹11.28	-₹14.24	₹11.64	₹2.83
Cash (Start of the year)	₹0.90	₹15.14	₹3.50	₹0.67
Cash (End of the year)	₹12.19	₹0.90	₹15.14	₹3.50

Balance Sheet · Consolidated

Balance Sheet · Consolidated — all values in INR Crore
Particulars	Mar 2026	Mar 2025	Mar 2024	Mar 2023
Non-Current Assets	₹984.62	₹899.01	₹804.48	₹786.28
Current Assets	₹1,250.11	₹1,135.24	₹896.23	₹727.70
Total Assets	₹2,234.73	₹2,034.25	₹1,700.71	₹1,513.98
Current Liabilities	₹169.08	₹184.06	₹142.16	₹191.84
Net Current Asset	₹1,081.03	₹951.18	₹754.08	₹535.86
Non-Current Liabilities	₹50.51	₹37.47	₹31.91	₹32.14
Equity Capital	₹2,015.14	₹1,812.72	₹1,526.65	₹1,290.00
Total Equity & Liabilities	₹2,234.73	₹2,034.25	₹1,700.71	₹1,513.98

Income Statement · Standalone

Income Statement · Standalone — all values in INR Crore
Particulars	Mar 2026	Mar 2025	Mar 2024	Mar 2023
Revenue	₹1,055.07	₹1,200.09	₹1,016.94	₹853.17
Other Income	₹52.73	₹44.45	₹33.78	₹35.31
Total Revenue	₹1,107.80	₹1,244.53	₹1,050.72	₹888.48
Total Expenses	₹753.09	₹748.66	₹641.53	₹568.42
Profit Before Tax	₹351.43	₹495.88	₹409.19	₹320.05
Tax	₹88.17	₹122.91	₹104.46	₹81.93
Profit After Tax	₹263.27	₹372.96	₹304.73	₹238.13
EPS - Basic	₹25.17	₹35.65	₹29.13	₹22.76
EPS - Diluted	₹25.17	₹35.65	₹29.13	₹22.76

Cash Flow · Standalone

Cash Flow · Standalone — all values in INR Crore
Particulars	Mar 2026	Mar 2025	Mar 2024	Mar 2023
Profit before tax	₹351.43	₹495.88	₹409.19	₹320.05
Income before WC changes	₹390.37	₹524.69	₹450.00	₹368.56
Change in Assets	-₹24.61	-₹216.44	-₹73.97	-₹79.46
Change in Liabilities	-₹4.51	₹45.68	-₹7.21	₹27.17
Change in WC	-₹29.12	-₹170.76	-₹81.18	-₹52.29
Cash flow from Operations	₹263.78	₹244.52	₹265.47	₹246.00
Cash flow from Investing	-₹142.28	-₹159.99	-₹154.61	-₹157.95
Cash flow from Financing	-₹114.51	-₹98.77	-₹99.21	-₹85.22
Total Cash Flow	₹6.98	-₹14.24	₹11.64	₹2.83
Cash (Start of the year)	₹0.90	₹15.14	₹3.50	₹0.67
Cash (End of the year)	₹7.89	₹0.90	₹15.14	₹3.50

Balance Sheet · Standalone

Balance Sheet · Standalone — all values in INR Crore
Particulars	Mar 2026	Mar 2025	Mar 2024	Mar 2023
Non-Current Assets	₹991.32	₹898.94	₹803.08	₹786.95
Current Assets	₹1,245.22	₹1,135.24	₹896.23	₹727.70
Total Assets	₹2,236.54	₹2,034.18	₹1,699.32	₹1,514.65
Current Liabilities	₹167.24	₹184.06	₹142.16	₹190.53
Net Current Asset	₹1,077.97	₹951.18	₹754.08	₹537.17
Non-Current Liabilities	₹49.54	₹37.47	₹31.91	₹32.14
Equity Capital	₹2,019.75	₹1,812.65	₹1,525.25	₹1,291.98
Total Equity & Liabilities	₹2,236.54	₹2,034.18	₹1,699.32	₹1,514.65

* All values are in INR Crore

Qty

Bid

150

1248.5

Ask

Qty

Bid Total: 150

Ask Total: 0

Buy orders: 100%

Sell orders: 0%

30 levels of bid & ask depth

Supply & Demand Zones

Bearish

Neutral

Bullish

Slightly Bullish

by SEBI experts available for this stock

Earn more using advisory

by SEBI experts

Expert Pick

EXPPICK

Stop-loss

Entry price

Target

Indicator

Value

Verdict

RSI (14)

44.59

Neutral

ATR (14)

44.83

Neutral

STOCH(9,6)

6.18

Bullish

STOCH RSI (14)

Bullish

ADX(9)

16.08

Bullish

UO(9)

41.14

Neutral

ROC(12)

-0.32

Bearish

WillR(14)

-84.07

Bullish

Period

Simple value

Exponential vaue

1311.82

1300.58

10D

1322.8

1308.84

20D

1301.24

1303.74

50D

1251.83

1263.45

100D

1182.52

1239.71

About Concord Biotech

ISIN

INE338H01029

Sector Market Cap

₹ 13,268 Cr

Concord Biotech Limited is an India-based research and development-driven biopharma company. The Company is engaged in the research and development, manufacturing, marketing, and selling of pharmaceutical products. Its business verticals include active pharmaceutical ingredients (API), finished formulations, and contract development and manufacturing services. It manufactures API through fermentation and semi-synthetic processes and finished formulations. The Company’s offerings span both biopharmaceutical APIs and formulations across therapeutic areas like immunosuppressants, oncology, anti-infectives nephrology, and critical care. Its portfolio also includes fermentation-based APIs in antibacterial, antifungal, and other therapeutic segments. Its API products include Mycophenolate Mofetil, Sirolimus, Pimecrolimus, Voclosporin, Mupirocin, Mupirocin Calcium, Vancomycin Hydrochloride, and Teicoplanin. Its API products under development include Daptomycin, Idarubicin, and Pirarubicin.

Concord Biotech Financial Highlights

Revenue: Concord Biotech reported revenue of ₹1,107.25 crore in FY26 vs ₹1,244.54 crore in FY25. It showed a decrease of 11.03% on a yearly basis.
Operating Profit: Concord Biotech reported an operating profit of ₹344.65 crore in FY26 vs ₹494.55 crore in FY25. It showed a decrease of 30.31% on a year-on-year basis.
Net Profit: Concord Biotech reported a net profit of ₹259.23 crore in FY26 vs ₹371.64 crore in FY25. It showed a decrease of 30.25% on a yearly basis.

Concord Biotech Quarterly Result Highlights

Concord Biotech reported revenue of ₹341.43 crore in Mar 2026, compared with ₹287.75 crore in Dec 2025, representing an increase of 18.66% on a quarter-on-quarter (QoQ) basis.
Concord Biotech reported an operating profit of ₹114.08 crore in Mar 2026, compared with ₹86.16 crore in Dec 2025, representing an increase of 32.40% on a quarter-on-quarter (QoQ) basis.
Concord Biotech reported a profit of ₹88.47 crore in Mar 2026, compared with ₹63.64 crore in Dec 2025, reflecting an increase of 39.02% on a QoQ basis.
The earnings per share (EPS) of Concord Biotech stood at ₹24.78 during Mar 2026.